ABSTRACT
Background Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.
Methods We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines.
Results Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. Third doses boosted antibody binding and function to higher levels than second-doses, and induced responses in older adults that were comparable in magnitude to those in younger adults. Humoral responses against Omicron were universally weaker than against the ancestral strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic health conditions, but not age per se, was the strongest consistent correlate of weaker humoral responses.
Conclusion Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation for Innovation through Exceptional Opportunities Fund -COVID-19 awards (to MAB, MD, MN, RP, ZLB) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for Health Research. LYL was supported by an SFU Undergraduate Research Award. GU and FHO hold Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figures 1, 2 and 3 updated to include new data after the second and third vaccine doses; Figure 4 added to show responses agains Omicron strain; Supplemental tables updated.
Data Availability
This is an interim report from an ongoing study. Data from this report are available upon reasonable request to the authors in accordance with REB and institutional data sharing requirements. At the end of the study, all data will be deposited in a national database maintained by the COVID-19 Immunity Task Force.